ConductScience.org, home

Library / Genes

JAK3: Janus kinase 3

1 protein, 114 patents, 22 drugs, 730 trials, 3,844 NIH grants and 9,117 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolJAK3HGNC
NameJanus kinase 3HGNC
NCBI Gene ID3718NCBI Gene
HGNC IDHGNC:6193HGNC
EnsemblENSG00000105639NCBI Gene
AliasesJAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAKNCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P52333Tyrosine-protein kinase JAK31,12442Ensembl, GeneID, HGNCUniProt

Patents 114

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
US 12539325 B22026-02-0355P52333Espacenet
JP 2026004568 A2026-01-1450473P52333Espacenet
JP 2026004568 A2026-01-1450474P52333Espacenet
EP 4650780 A22025-11-1912466P52333Espacenet
EP 4641201 A22025-10-2913667P52333Espacenet
JP 2025517969 A2025-06-1213667P52333Espacenet
JP 2025517970 A2025-06-1212466P52333Espacenet
US 12133879 B22024-11-0555P52333Espacenet
JP 2024530024 A2024-08-1410P52333Espacenet
KR 1020240095531 A2024-06-2510P52333Espacenet

Drugs 22

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
AT-9283CHEMBL495727Tyrosine-protein kinase JAK3 inhibitorINHIBITORChEMBL
CERDULATINIBCHEMBL4116008Tyrosine-protein kinase JAK3 inhibitorINHIBITORChEMBL
DECERNOTINIBCHEMBL3039513Tyrosine-protein kinase JAK3 inhibitorINHIBITORChEMBL
DELGOCITINIBCHEMBL4297507Janus Kinase (JAK) inhibitorINHIBITORChEMBL
DEURUXOLITINIB PHOSPHATECHEMBL4594382Tyrosine-protein kinase JAK3 inhibitorINHIBITORChEMBL
FILGOTINIBCHEMBL3301607Tyrosine-protein kinase JAK3 inhibitorINHIBITORChEMBL
FILGOTINIB MALEATECHEMBL4298167Tyrosine-protein kinase JAK3 inhibitorINHIBITORChEMBL
GUSACITINIBCHEMBL4594275Janus Kinase (JAK) inhibitorINHIBITORChEMBL
IZENCITINIBCHEMBL4650343Janus Kinase (JAK) inhibitorINHIBITORChEMBL
NEZULCITINIBCHEMBL4802163Janus Kinase (JAK) inhibitorINHIBITORChEMBL

Trials 730

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07598643TOFACITINIBPHASE2ClinicalTrials.gov
NCT07597577UPADACITINIBClinicalTrials.gov
NCT07595939RUXOLITINIBPHASE3ClinicalTrials.gov
NCT07588568UPADACITINIBPHASE2ClinicalTrials.gov
NCT07581418TOFACITINIBClinicalTrials.gov
NCT07576010RUXOLITINIBPHASE1ClinicalTrials.gov
NCT07566897RUXOLITINIBPHASE1ClinicalTrials.gov
NCT07554820TOFACITINIBPHASE4ClinicalTrials.gov
NCT07554495FILGOTINIBPHASE3ClinicalTrials.gov
NCT07553182FILGOTINIBPHASE3ClinicalTrials.gov

NIH grants 3844

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant742,025NIH's project files
P30CA021765Cancer Center Support Grant (CCSG)472,025NIH's project files
P30CA008748Cancer Center Support Grant452,025NIH's project files
ZIAAR041159Cytokine Signaling, Immunoregulation and Autoimmune and Immunodeficiency Diseases292,025NIH's project files
R13AI094943Annual Primary Immune Deficiency Treatment Consortium (PIDTC) Workshop and Education Day202,025NIH's project files
UL1TR001863Yale Clinical and Translational Science Award202,025NIH's project files
ZIAAI001222Characterization of the cellular and molecular bases of inborn errors of immunity192,025NIH's project files
ZICAR041181Translational Immunology research: a support for clinical immunological research192,025NIH's project files
P30CA016058Cancer Center Support Grant182,025NIH's project files
ZIAHL005401IL-2 Family Cytokines and their Receptors-- Biology of the IL-2 system142,025NIH's project files

Papers 9117

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42825998PubTator, text miningPubMed
42824469PubTator, text miningPubMed
42823604PubTator, text miningPubMed
42811980PubTator, text miningPubMed
42804788PubTator, text miningPubMed
42789172PubTator, text miningPubMed
42777315PubTator, text miningPubMed
42766692PubTator, text miningPubMed
42751103PubTator, text miningPubMed
42750356PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license